Recent Advances in the Treatment of Mantle Cell Lymphoma : Episode 4

Is There a Role for Response-Adapted Treatment in Mantle Cell Lymphoma?

Jan 24, 2023

By Alexey V. Danilov, MD, PhD
Bijal D. Shah, MD
Matthew J. Matasar, MD
Boyu Hu, MD

Matthew J. Matasar, MD, discusses the prospect of using minimal residual disease to guide treatment decisions in mantle cell lymphoma.

EP: 1.Overview of Mantle Cell Lymphoma and First-Line Treatment Options

EP: 2.Patient Profile 1: A 74-Year-Old Man Diagnosed With Mantle Cell Lymphoma

EP: 3.TRIANGLE Study: Ibrutinib vs Stem Cell Transplant in Younger Patients With MCL

EP: 4.Is There a Role for Response-Adapted Treatment in Mantle Cell Lymphoma?

Related Videos

Related Content

FDA Approves Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

January 27th 2023

Brody Previews ASH 2022 Data With Pirtobrutinib, CAR T-cell Therapy, and Glofitamab in MCL

December 8th 2022

R-DHAP Regimen Produces Favorable Efficacy in Younger MCL Patients

January 16th 2023

Wang Reflects on Ibrutinib’s Role and Emerging Research in MCL Management

January 20th 2022

Brexu-cel Elicits Durable Responses in High-Risk Relapsed/Refractory MCL

January 13th 2023

FDA Grants Orphan Drug Designation to LP-284 for Mantle Cell Lymphoma

January 9th 2023

FDA Approves Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

January 27th 2023

Brody Previews ASH 2022 Data With Pirtobrutinib, CAR T-cell Therapy, and Glofitamab in MCL

December 8th 2022

R-DHAP Regimen Produces Favorable Efficacy in Younger MCL Patients

January 16th 2023

Wang Reflects on Ibrutinib’s Role and Emerging Research in MCL Management

January 20th 2022

Brexu-cel Elicits Durable Responses in High-Risk Relapsed/Refractory MCL

January 13th 2023

FDA Grants Orphan Drug Designation to LP-284 for Mantle Cell Lymphoma

January 9th 2023

FDA Approves Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

January 27th 2023

Brody Previews ASH 2022 Data With Pirtobrutinib, CAR T-cell Therapy, and Glofitamab in MCL

December 8th 2022

R-DHAP Regimen Produces Favorable Efficacy in Younger MCL Patients

January 16th 2023

Wang Reflects on Ibrutinib’s Role and Emerging Research in MCL Management

January 20th 2022

Brexu-cel Elicits Durable Responses in High-Risk Relapsed/Refractory MCL

January 13th 2023

FDA Grants Orphan Drug Designation to LP-284 for Mantle Cell Lymphoma

January 9th 2023

Related Content

FDA Approves Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

January 27th 2023

Brody Previews ASH 2022 Data With Pirtobrutinib, CAR T-cell Therapy, and Glofitamab in MCL

December 8th 2022

R-DHAP Regimen Produces Favorable Efficacy in Younger MCL Patients

January 16th 2023

Wang Reflects on Ibrutinib’s Role and Emerging Research in MCL Management

January 20th 2022

Brexu-cel Elicits Durable Responses in High-Risk Relapsed/Refractory MCL

January 13th 2023

FDA Grants Orphan Drug Designation to LP-284 for Mantle Cell Lymphoma

January 9th 2023

Editorial Board

CancerNetwork.com

OncNursingNews.com

TargetedOnc.com

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

© 2023 MJH Life Sciences

All rights reserved.